JP2016513130A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513130A5 JP2016513130A5 JP2015559501A JP2015559501A JP2016513130A5 JP 2016513130 A5 JP2016513130 A5 JP 2016513130A5 JP 2015559501 A JP2015559501 A JP 2015559501A JP 2015559501 A JP2015559501 A JP 2015559501A JP 2016513130 A5 JP2016513130 A5 JP 2016513130A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- saturated
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 229920006395 saturated elastomer Polymers 0.000 claims 16
- 125000005843 halogen group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 230000001588 bifunctional effect Effects 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000002837 carbocyclic group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000007278 cognition impairment Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382065.4 | 2013-03-01 | ||
| EP13382065 | 2013-03-01 | ||
| PCT/EP2014/053877 WO2014131855A1 (en) | 2013-03-01 | 2014-02-27 | Novel compounds as dual inhibitors of phosphodiesterases and histone deacetylases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513130A JP2016513130A (ja) | 2016-05-12 |
| JP2016513130A5 true JP2016513130A5 (enExample) | 2017-03-30 |
| JP6338601B2 JP6338601B2 (ja) | 2018-06-06 |
Family
ID=47901928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015559501A Expired - Fee Related JP6338601B2 (ja) | 2013-03-01 | 2014-02-27 | ホスホジエステラーゼとヒストンデアセチラーゼの二重阻害剤としての新規な化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9573956B2 (enExample) |
| EP (1) | EP2961741B1 (enExample) |
| JP (1) | JP6338601B2 (enExample) |
| CA (1) | CA2908482A1 (enExample) |
| DK (1) | DK2961741T3 (enExample) |
| ES (1) | ES2635016T3 (enExample) |
| WO (1) | WO2014131855A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9505767B2 (en) * | 2013-09-05 | 2016-11-29 | Genentech, Inc. | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors |
| EP3085700B1 (en) * | 2013-12-20 | 2018-10-31 | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | Novel piperidine carboxamide compound, preparation method, and usage thereof |
| CA2987978C (en) * | 2014-06-16 | 2022-08-16 | Fundacion Para La Investigacion Medica Aplicada | Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases |
| JP2017523204A (ja) * | 2014-08-04 | 2017-08-17 | ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ | 認知向上のために用いる新規化合物 |
| WO2016120432A1 (en) * | 2015-01-30 | 2016-08-04 | Fundación Para La Investigación Médica Aplicada | Compounds and methods for anticoagulation therapy |
| CN104610166B (zh) * | 2015-03-10 | 2017-06-13 | 山东大学 | 嘧啶苄基异羟肟酸类组蛋白去乙酰化酶抑制剂及制备方法和应用 |
| HK1249104A1 (zh) | 2015-03-13 | 2018-10-26 | Forma Therapeutics, Inc. | 作为HDAC8抑制剂的α-肉桂酰胺化合物和组合物 |
| KR102457316B1 (ko) * | 2015-06-26 | 2022-10-20 | 총킹 디캉 에릴 파마 씨오. 엘티디. | 새로운 5형포스포디에스테라아제 억제제 및 그 용도 |
| CN110337437B (zh) | 2016-12-28 | 2023-02-03 | 达特神经科学有限公司 | 作为pde2抑制剂的取代的吡唑并嘧啶酮化合物 |
| CN107163052B (zh) * | 2017-04-18 | 2020-08-11 | 华南农业大学 | 一种针对多种pde-5抑制剂药物的免疫检测方法 |
| WO2019018562A1 (en) | 2017-07-19 | 2019-01-24 | Ideaya Biosciences, Inc. | AMIDO COMPOUND AS MODULATORS OF AHR |
| CN108912029B (zh) * | 2017-08-25 | 2021-10-01 | 广东东阳光药业有限公司 | 含氮杂环酰胺衍生物及其用途 |
| KR102794907B1 (ko) | 2017-11-27 | 2025-04-14 | 다트 뉴로사이언스, 엘엘씨 | Pde1 억제제로서의 치환된 푸라노피리미딘 화합물 |
| CN110054625B (zh) * | 2018-01-18 | 2022-01-07 | 山东大学 | N-酰基苯磺酰胺异羟肟酸类Bcl-2、HDAC双靶点抑制剂及制备方法和应用 |
| CN108558890A (zh) * | 2018-06-28 | 2018-09-21 | 重庆康刻尔制药有限公司 | 一种西地那非中间体合成方法 |
| CN109824516B (zh) * | 2019-03-14 | 2021-07-23 | 泰州精英化成医药科技有限公司 | 一种反式-4-羟基环已烷甲酸叔丁酯的制备方法 |
| CN109810108B (zh) * | 2019-03-20 | 2021-08-06 | 华东理工大学 | 2,8-二氮杂-螺-[4,5]-癸烷类嘧啶-异羟肟酸化合物及其用途 |
| US11787812B2 (en) | 2020-12-11 | 2023-10-17 | Ildong Pharmaceutical Co., Ltd. | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors |
| KR20240124952A (ko) | 2021-12-22 | 2024-08-19 | 어거스틴 테라퓨틱스 | Hdac6 억제제로서의 화합물 및 이의 용도 |
| CN115417877B (zh) * | 2022-09-20 | 2024-05-14 | 杭州师范大学 | 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用 |
| CN116375714A (zh) * | 2023-03-24 | 2023-07-04 | 苏州满元生物科技有限公司 | 卡巴地那非类药物关键中间体的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003210447B2 (en) * | 2002-01-04 | 2008-02-07 | Henry Ford Health System | Nitric oxide donors for treatment of disease and injury |
| CN1548438A (zh) * | 2003-05-16 | 2004-11-24 | 烟台开发区北方药物研究所 | 2-取代苯基-6,8-二烃基-3H-咪唑[1,5α][1,3,5]三嗪-4-酮衍生物,其制备方法及其药物用途 |
| DE602005017135D1 (de) * | 2004-03-05 | 2009-11-26 | Nycomed Gmbh | Neue verwendung von pde5-hemmern |
| CA2661483A1 (en) * | 2006-08-24 | 2008-02-28 | Surface Logix, Inc. | Pharmacokinetically improved 2-phenyl-substituted imidazotriazinone derivatives and their use |
| EP2061772A4 (en) * | 2006-09-11 | 2011-06-29 | Curis Inc | MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES |
| JP2010527928A (ja) * | 2007-05-18 | 2010-08-19 | ヴィヴァス・インコーポレイテッド | ホスホジエステラーゼ−５阻害剤を含む新規の組み合わせおよびそれらの使用 |
| NZ603725A (en) * | 2010-08-12 | 2015-04-24 | Boehringer Ingelheim Int | 6-cycloalkyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
| EP2535049A1 (en) * | 2011-06-17 | 2012-12-19 | Proyecto de Biomedicina Cima, S.L. | Tadalafil for the treatment of dementia |
-
2014
- 2014-02-27 EP EP14707155.9A patent/EP2961741B1/en not_active Not-in-force
- 2014-02-27 JP JP2015559501A patent/JP6338601B2/ja not_active Expired - Fee Related
- 2014-02-27 CA CA2908482A patent/CA2908482A1/en not_active Abandoned
- 2014-02-27 ES ES14707155.9T patent/ES2635016T3/es active Active
- 2014-02-27 US US14/770,065 patent/US9573956B2/en not_active Expired - Fee Related
- 2014-02-27 WO PCT/EP2014/053877 patent/WO2014131855A1/en not_active Ceased
- 2014-02-27 DK DK14707155.9T patent/DK2961741T3/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513130A5 (enExample) | ||
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| CL2020001343A1 (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| JP2019524883A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2015505296A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| JP2016503797A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2014051526A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| EA201592146A1 (ru) | Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам | |
| CL2013002690A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| MX382122B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| JP2016505614A5 (enExample) | ||
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
| CO2017013101A2 (es) | Derivado de urea o sal farmacológicamente aceptable del mismo | |
| EA201791829A1 (ru) | Амидные соединения в качестве агонистов рецептора 5-ht | |
| JP2016522254A5 (enExample) | ||
| EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral |